Categories
Change Password!
Reset Password!
The main aim of the study was to investigate the effectiveness of bismuth combined with triple therapy as a first‐line treatment for Helicobacter pylori (H. pylori) infection.
Addressing the rising
antibiotic resistance, especially clarithromycin resistance which affects the Helicobacter
pylori eradication therapy is quite challenging. In this study, the use of bismuth and triple
therapy was found to be effective for this
bacterial infection based on elevated eradication rates and high clarithromycin tolerance.
The main aim
of the study was to investigate the effectiveness of
bismuth combined with triple therapy as a first‐line treatment for Helicobacter
pylori (H. pylori) infection.
One hundred and seven patients infected
with H. pylori on H. pylori eradication therapy (combination of
bismuth and triple therapy) for 2 weeks were included. Dual‐priming
oligonucleotide‐based multiplex PCR was used to assess the clarithromycin
resistance rate.
One hundred
and four patients completed this combination therapy.
High bacterial eradication rate i.e. 87.9% and 90.4% was observed as per the
intention-to-treat analysis and per protocol analysis. Occurrence of
clarithromycin resistance was 33.6% (35 patients out of 104 patients), and
eradication rate was 77.1% in resistant strains (27 patients out of 35
patients).
In
patients with clarithromycin‐resistant strains, the combined use of Bismuth and
triple therapy could serve as a suitable first‐line treatment routine for H.
pylori eradication. Especially, in
patients with high clarithromycin tolerance, bismuth when used as an add‐on
therapy can be regarded as a first‐line treatment routine.
Helicobacter
Efficacy of bismuth added to standard triple therapy as the first‐line eradication regimen for Helicobacter pylori infection
Yeon‐Ji Kim et al.
Comments (0)